Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain Barrier

We attempted to assess regional differences in cerebral P-glycoprotein (P-gp) function by performing paired positron emission tomography (PET) scans with the P-gp substrate (R)-[11C]verapamil in five healthy subjects before and after i.v. infusion of tariquidar (2 mg/kg). Comparison of tariquidar-induced changes in distribution volumes (DVs) in 42 brain regions of interest (ROIs) failed to detect significant differences among brain ROIs. Statistical parametric mapping analysis of parametric DV images visualized symmetrical bilateral clusters with moderately higher DV increases in response to tariquidar administration in cerebellum, parahippocampal gyrus, olfactory gyrus, and middle temporal lobe and cortex, which might reflect moderately decreased P-gp function and expression.

[1]  W. Löscher,et al.  Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PET , 2008, Journal of Nuclear Medicine.

[2]  Mark Lubberink,et al.  Evaluation of Tracer Kinetic Models for Quantification of P-Glycoprotein Function using (R)-[11C]Verapamil and PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Alexander Hammers,et al.  Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.

[4]  D. Mankoff,et al.  Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography , 2005, Clinical pharmacology and therapeutics.

[5]  Wolfgang Löscher,et al.  Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases , 2005, Progress in Neurobiology.

[6]  Rudie Kortekaas,et al.  Blood–brain barrier P-glycoprotein function decreases in specific brain regions with aging: A possible role in progressive neurodegeneration , 2009, Neurobiology of Aging.

[7]  P. Herscovitch,et al.  P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using 11C-N-Desmethyl-Loperamide in Monkeys , 2008, Journal of Nuclear Medicine.

[8]  Stephan Kopp,et al.  A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood–Brain Barrier with (R)-11C-Verapamil and PET , 2009, Journal of Nuclear Medicine.

[9]  Alexander Hammers,et al.  Pharmacoresistance in Epilepsy : A Pilot PET Study with the P-Glycoprotein Substrate R-[ 11 C ] verapamil ∗ † , 2007 .

[10]  Elizabeth Fox,et al.  Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor , 2007, Expert review of anticancer therapy.

[11]  J Nucl Med , 2010 .

[12]  M. Lubberink,et al.  Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Elizabeth C M de Lange,et al.  Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. , 2004, Advanced drug delivery reviews.

[14]  W. Löscher,et al.  Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[11C]verapamil PET , 2010, European Journal of Nuclear Medicine and Molecular Imaging.